Distribution and clinical significance of heparan sulfate proteoglycans in ovarian cancer

E. June Davies, Fiona H. Blackhall, Jonathan H. Shanks, Guido David, Alan T. McGown, Ric Swindell, Richard J. Slade, Pierre Martin-Hirsch, John T. Gallagher, Gordon C. Jayson

    Research output: Contribution to journalArticlepeer-review

    Abstract

    Purpose: Heparan sulfate proteoglycans have been implicated in cancer cell growth, invasion, metastasis, and angiogenesis. This study was designed to compare their expression in normal ovary and ovarian tumors and then to examine their prognostic significance in ovarian cancer. Experimental Design: The expression of syndecan-1, -2, -3, and -4, glypican-1, and perlecan was assessed by immunohistochemistry in 147 biopsies that included normal ovary and benign, borderline, and malignant ovarian tumors. Clinical data, including tumor stage, performance status, treatment, and survival, were collected. Univariate and multivariate analyses were performed to evaluate prognostic significance. Results: The expression patterns of syndecan-1 and perlecan were altered in ovarian tumors compared with normal ovary. Syndecan-1 was not detected in normal ovary but was present in the epithelial and stromal cells of benign and borderline tumors and in ovarian adenocarcinomas. Perlecan expression was decreased in basement membranes that were disrupted by cancer cells but maintained in the basement membranes of blood vessels. Syndecan-2, -3, and -4, and glypican-1 were expressed in normal ovary and benign and malignant ovarian tumors. Stromal expression of syndecan-1 and glypican-1 were poor prognostic factors for survival in univariate analysis. Conclusion: We report for the first time distinct patterns of expression of cell surface and extra cellular matrix heparan sulfate proteoglycans in normal ovary compared with ovarian tumors. These data reinforce the role of the tumor stroma in ovarian adenocarcinoma and suggest that stromal induction of syndecan-1 contributed to the pathogenesis of this malignancy.
    Original languageEnglish
    Pages (from-to)5178-5186
    Number of pages8
    JournalClinical Cancer Research
    Volume10
    Issue number15
    DOIs
    Publication statusPublished - 1 Aug 2004

    Fingerprint

    Dive into the research topics of 'Distribution and clinical significance of heparan sulfate proteoglycans in ovarian cancer'. Together they form a unique fingerprint.

    Cite this